Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Rhea-AI Summary

Cyteir Therapeutics (Nasdaq: CYT) announced that its CEO, Markus Renschler, will present at the 2022 Jefferies Healthcare Conference on June 10, 2022, at 11:00 a.m. ET in New York City. The event will be available for live viewing via webcast on their website. Cyteir focuses on developing synthetically lethal therapies for cancer, with its lead compound, CYT-0851, currently undergoing clinical trials for hematologic and solid tumors.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that Markus Renschler, MD, President and Chief Executive Officer will participate in a presentation at the 2022 Jefferies Healthcare Conference. The meeting is being held in person in New York City on Friday, June 10, 2022 at 11:00 a.m. ET.

A live webcast of the presentation will be available in the Investors & Media section of the Cyteir website at www.cyteir.com. A webcast replay will also be available on the website shortly after conclusion of the event for 30 days.

About Cyteir Therapeutics, Inc.

Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. At Cyteir, we employ an integrated target discovery approach that incorporates a critical evaluation of the target biology with internal and external information from a variety of genetic and chemical synthetic lethality screens to fuel our drug discovery and development pipeline. Cyteir’s wholly owned lead compound, CYT-0851, is a selective oral investigational drug currently in a Phase 1/2 clinical trial for hematologic cancers and solid tumors. Follow Cyteir on social media: LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005297/en/

INVESTOR CONTACT:

Lisa Hayes

Vice President, Investor Relations and Corporate Communications

908-868-8926

Lisa.Hayes@cyteir.com

MEDIA CONTACT:

Michele Parisi

925-429-1850

mparisi@forwardhealthinc.com

Source: Cyteir Therapeutics

FAQ

When will Markus Renschler present at the Jefferies Healthcare Conference for Cyteir Therapeutics?

Markus Renschler will present on June 10, 2022, at 11:00 a.m. ET.

Where can I watch the Cyteir Therapeutics presentation live?

The presentation can be viewed live on the Cyteir website in the Investors & Media section.

What is the focus of Cyteir Therapeutics?

Cyteir Therapeutics is focused on the discovery and development of next-generation synthetically lethal therapies for cancer.

What is CYT-0851 in relation to Cyteir Therapeutics?

CYT-0851 is Cyteir's lead investigational drug currently in Phase 1/2 clinical trials for hematologic cancers and solid tumors.